Adding metyrapone to chemotherapy plus mitotane for Cushing's syndrome due to advanced adrenocortical carcinoma (original) (raw)

Effectiveness of metyrapone in treating Cushing's Syndrome: a retrospective multicenter study in 195 patients

The Journal of clinical endocrinology and metabolism, 2015

Preoperative treatment with metyrapone in patients with Cushing’s syndrome due to adrenal adenoma: a pilot prospective study

Giuseppe Reimondo

Endocrine Connections

View PDFchevron_right

Efficiency and tolerance of mitotane in Cushing's disease in 76 patients from a single center

S. Silvera

European Journal of Endocrinology, 2012

View PDFchevron_right

Assessment of serum-free cortisol levels in patients with adrenocortical carcinoma treated with mitotane: a pilot study

Gregory Kaltsas

Clinical Endocrinology, 2010

View PDFchevron_right

Management of Endocrine Manifestations and the Use of Mitotane As a Chemotherapeutic Agent for Adrenocortical Carcinoma

Lynnette Nieman

Journal of Clinical Oncology, 2009

View PDFchevron_right

Medical Treatment of Cushing’s Syndrome: Adrenal-Blocking Drugs and Ketaconazole

Wouter Herder

Neuroendocrinology, 2010

View PDFchevron_right

Merits and pitfalls of mifepristone in Cushing's syndrome

P. Bouchard

European Journal of Endocrinology, 2009

View PDFchevron_right

Adrenal Cushing Syndrome Diagnosed During Pregnancy: Successful Medical Management With Metyrapone

Stan Van Uum

Journal of the Endocrine Society

View PDFchevron_right

Medical management of Cushing disease

James Chandler

Neurosurgical FOCUS, 2007

View PDFchevron_right

New developments in the medical treatment of Cushing's syndrome

Leo Hofland

Endocrine-Related Cancer, 2012

View PDFchevron_right

Inhibition by estrogen administration of adrenal-pituitary response to methopyrapone

Jorge Mestman

Journal of Clinical Investigation, 1963

View PDFchevron_right

Medical Treatment of Cushing’s Syndrome: Glucocorticoid Receptor Antagonists and Mifepristone

Thierry Brue

Neuroendocrinology, 2010

View PDFchevron_right

Medical treatment of Cushing's disease: Overview and recent findings

Livia Barba

International Journal of General Medicine, 2009

View PDFchevron_right

Effects of mitotane on the hypothalamic–pituitary–adrenal axis in patients with adrenocortical carcinoma

Giuseppe Reimondo

European Journal of Endocrinology

View PDFchevron_right

Medical combination therapies in Cushing’s disease

Lucio Vilar

Pituitary, 2015

View PDFchevron_right

Review Article Management Strategies for Aggressive Cushing’s Syndrome: From

Chiara Graziadio

2016

View PDFchevron_right

Treatment of Cushing’s Syndrome: An Endocrine Society Clinical Practice Guideline

Lynnette Nieman

The Journal of Clinical Endocrinology & Metabolism, 2015

View PDFchevron_right

The superiority of the metyrapone test versus the high-dose dexamethasone test in the differential diagnosis of Cushing's syndrome

George Griffing

The American Journal of Medicine, 1983

View PDFchevron_right

Efficacy and safety of osilodrostat in patients with Cushing's disease (LINC 3): a multicentre phase III study with a double-blind, randomised withdrawal phase

Rattana Leelawattana

The Lancet Diabetes & Endocrinology, 2020

View PDFchevron_right

Effects of mitotane treatment on human steroid metabolism: implications for patient management

Simon Aylwin

Endocrine Connections, 2012

View PDFchevron_right

Clinical Experience with Ketoconazole as a Therapy for Patients with Cushing's Syndrome

Leon Scott Kennedy

Clinical Endocrinology, 1987

View PDFchevron_right

Prognostic factors and mitotane treatment of adrenocortical cancer. Two decades of experience from an institutional case series

Andrea Uhlyarik

Frontiers in Endocrinology, 2022

View PDFchevron_right

Role of Ketoconazole Treatment in Urinary-Free Cortisol-to-Cortisone and Tetrahydrocortisol-to-Tetrahydrocortisone Ratios in Nonectopic Cushing's Syndrome

Luis Jimenez

Endocrine, 2002

View PDFchevron_right

Jerzy Adamski

European journal of endocrinology, 2017

View PDFchevron_right

Medical Treatment of Cushing’s Disease with Pasireotide

Andre Lacroix

European Endocrinology, 2010

View PDFchevron_right

Preoperative Normalization of Cortisol Levels in Cushing's Disease After Medical Treatment: Consequences for Somatostatin and Dopamine Receptor Subtype Expression and In Vitro Response to Somatostatin Analogs and Dopamine Agonists

Leo Hofland

The Journal of Clinical Endocrinology & Metabolism, 2013

View PDFchevron_right

Somatostatin and dopamine receptors as targets for medical treatment of Cushing’s Syndrome

Leo Hofland

Reviews in Endocrine and Metabolic Disorders, 2008

View PDFchevron_right

Pseudo-Cushing Syndrome With an Atypically High Cortisol Burden and Clinical Improvement With Adrenal Enzyme Inhibitor

Chris Gilfillan

JCEM Case Reports

View PDFchevron_right

A New Fluorimetric Method of Plasma Cortisol Assay with a Study of Pituitary—Adrenal Function Using Metyrapone (Su. 4885)

Victor Yesavage

Journal of Endocrinology, 1963

View PDFchevron_right

Mifepristone Treatment of Cushing's Syndrome in a Pediatric Patient

Neyssa Marina

Pediatrics, 2015

View PDFchevron_right

Randomized Trial of Osilodrostat for the Treatment of Cushing Disease

Zhanna Belaya

The Journal of Clinical Endocrinology & Metabolism, 2022

View PDFchevron_right

Ketoconazole blocks cortisol secretion in man by inhibition of adrenal 11 β -hydroxylase

Jasper Engelhardt

Journal of Molecular Medicine-jmm, 1985

View PDFchevron_right

Treatment of Adrenocorticotropin-Dependent Cushing’s Syndrome: A Consensus Statement

alessia caldoro

The Journal of Clinical Endocrinology & Metabolism, 2008

View PDFchevron_right

Adding metyrapone to chemotherapy plus mitotane for Cushing's syndrome due to advanced adrenocortical carcinoma (original) (raw)

Related papers